Alzamend Neuro, Inc.
ALZN
$1.89
-$0.03-1.56%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 919.00K | 821.80K | 959.30K | 688.80K | 590.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.20M | 998.10K | 2.70M | 1.14M | 1.04M |
| Operating Income | -2.20M | -998.10K | -2.70M | -1.14M | -1.04M |
| Income Before Tax | -2.20M | -1.00M | -2.70M | -1.14M | -1.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.20M | -1.00M | -2.70M | -1.14M | -1.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.20M | -1.00M | -2.70M | -1.14M | -1.04M |
| EBIT | -2.20M | -998.10K | -2.70M | -1.14M | -1.04M |
| EBITDA | -2.17M | -970.40K | -2.67M | -1.13M | -1.02M |
| EPS Basic | -0.58 | -0.30 | -1.28 | -2.43 | -1.75 |
| Normalized Basic EPS | -0.36 | -0.19 | -0.80 | -1.00 | -1.06 |
| EPS Diluted | -0.58 | -0.30 | -1.28 | -2.43 | -1.75 |
| Normalized Diluted EPS | -0.36 | -0.19 | -0.80 | -1.00 | -1.06 |
| Average Basic Shares Outstanding | 3.80M | 3.38M | 2.11M | 711.30K | 612.00K |
| Average Diluted Shares Outstanding | 3.80M | 3.38M | 2.11M | 711.30K | 612.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |